Alaunos Prices $1.12M Registered Direct Offering

Fairmount Funds Management LLC disclosed a 19.99% stake in Alaunos Therapeutics, Inc. (TCRT) through a Schedule 13D filing. The investment includes preferred-share rights and potential board changes, with Fairmount designees set to fill three of five board seats upon shareholder approval. The stake is capped at 19.99% and will reduce to 9.99% if ownership falls below 9%. Fairmount backed Alaunos's merger with Velaris and a $350 million financing.

Alaunos Therapeutics (TCRT) stock surged 146.67% to $2.59 on news of acquiring Velaris Therapeutics and a $350M private placement. The acquisition expands Alaunos' pipeline with therapies for pulmonary arterial hypertension and related conditions. The company expects financial runway into 2029, with proof-of-concept data for VLR199 anticipated in 2028.

Alaunos Therapeutics (TCRT) completed its acquisition of Velaris Therapeutics and raised $350 million in a private placement. The funds will support operations and clinical trials until 2029. Peter Harwin of Fairmount will join the board, and stock conversions will increase common shares to 358.59 million.

Alaunos Therapeutics (TCRT) acquired Velaris Therapeutics and secured $350M in private placement funding. The company expects financial runway into 2029 and clinical proof-of-concept data for VLR199 in 2028. Alaunos is shifting focus to cardiopulmonary assets with multiyear financial support.

Alaunos Therapeutics (NASDAQ: TCRT) acquired Velaris Therapeutics, a biotech company developing treatments for pulmonary hypertension. The deal was funded by a $350M private placement, giving Alaunos financial runway into 2029. Velaris's pipeline includes VLR199, with proof-of-concept data expected in 2028.

Alaunos Therapeutics (TCRT) acquired Velaris in a stock-for-stock merger and secured $350M in PIPE financing to advance Velaris programs. The company also signed agreements for board changes, registration rights, and a discovery pact with Paragon Laboratories.